ENRIQUE A. FLORES
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
- Where
- Covington, GA
- NPI
- 1134170517
- Received
- $40,784 in 48 records, 2019 to 2025
- As principal investigator
- $206,132 of research payments to others in 225 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 9 | $191 |
| 2024 | General payment | 6 | $129 |
| 2023 | General payment | 1 | $16 |
| 2022 | General payment | 9 | $227 |
| 2021 | General payment | 6 | $119 |
| 2020 | General payment | 2 | $27 |
| 2019 | General payment | 15 | $40,072 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merit Medical Systems Inc | 7 | $39,250 | 2019 |
| Terumo Medical Corporation | 6 | $785 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 4 | $90 | 2024–2025 |
| AstraZeneca Pharmaceuticals LP | 5 | $85 | 2019–2022 |
| Janssen Pharmaceuticals, Inc | 3 | $75 | 2021–2022 |
| Abbott Laboratories | 3 | $68 | 2022–2024 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 | 2024–2025 |
| Teleflex LLC | 1 | $55 | 2022 |
| ABIOMED | 2 | $54 | 2022 |
| Surmodics, Inc. | 3 | $48 | 2023–2025 |
| Medtronic, Inc. | 3 | $48 | 2021–2024 |
| Novartis Pharmaceuticals Corporation | 2 | $43 | 2022–2025 |
| HEARTFLOW, INC. | 1 | $37 | 2025 |
| Amgen Inc. | 2 | $32 | 2020–2025 |
| Edwards Lifesciences Corporation | 1 | $27 | 2024 |
| Chiesi USA, Inc. | 1 | $14 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $12 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 7 | $39,250 |
| Food and Beverage | 37 | $865 |
| Travel and Lodging | 3 | $623 |
| Education | 1 | $45 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-06 | E.R. Squibb & Sons, L.L.C. | $25 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-09-11 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-03 | Surmodics, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Pounce Thrombectomy Device, Pounce Arterial Packaged Assembly, Sterile | 2025 | |
| 2025-08-28 | HEARTFLOW, INC. | $37 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-08-14 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-06-12 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-03-26 | Surmodics, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Pounce Thrombectomy Device, Pounce Arterial Packaged Assembly, Sterile | 2025 | |
| 2025-02-13 | Actelion Pharmaceuticals US, Inc. | $18 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2024-11-13 | Abbott Laboratories | $25 | Food and Beverage | In-kind items and services | CARDIOMEMS Device, Heart Failure | 2024 | |
| 2024-10-11 | Medtronic, Inc. | $14 | Food and Beverage | In-kind items and services | ONYX FRONTIER Device, Stents | 2024 | |
| 2024-10-10 | Actelion Pharmaceuticals US, Inc. | $21 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2024 | |
| 2024-09-05 | Actelion Pharmaceuticals US, Inc. | $16 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2024 | |
| 2024-08-22 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2024 | |
| 2024-02-20 | Edwards Lifesciences Corporation | $27 | Food and Beverage | In-kind items and services | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2024 | |
| 2023-11-13 | Surmodics, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Sublime 014 Rx PTA Balloon Dilatation Catheter Device, Peripheral angioplasty balloon catheter | 2023 | |
| 2022-12-01 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LEQVIO Drug, CARDIOVASCULAR | 2022 | |
| 2022-11-10 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-09-28 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-08-09 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | HeartMate Touch Device, Heart Failure | 2022 | |
| 2022-07-20 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-06-29 | Teleflex LLC | $55 | Food and Beverage | In-kind items and services | MANTA Device, Interventional Access | 2022 | |
| 2022-03-15 | ABIOMED | $26 | Food and Beverage | In-kind items and services | Impella Device, Cardiology/Vascular Diseases | 2022 | |
| 2022-03-03 | Abbott Laboratories | $22 | Food and Beverage | In-kind items and services | HeartMate Touch Device, Heart Failure | 2022 | |
| 2022-02-22 | ABIOMED | $28 | Food and Beverage | In-kind items and services | Impella Device, Cardiology/Vascular Diseases | 2022 | |
| 2021-12-10 | Janssen Pharmaceuticals, Inc | $45 | Education | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-08-26 | Merck Sharp & Dohme LLC | $12 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2021 | |
| 2021-08-11 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-07-27 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-03-24 | Medtronic, Inc. | $17 | Food and Beverage | In-kind items and services | HawkOne Device, Directional Atherectomy Devices | 2021 | |
| 2021-02-03 | Medtronic, Inc. | $15 | Food and Beverage | In-kind items and services | Resolute Device, Stents | 2021 | |
| 2020-12-10 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2020 | |
| 2020-02-10 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2019-08-31 | Merit Medical Systems Inc | $6,800 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-08-31 | Merit Medical Systems Inc | $3,500 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-07-26 | Terumo Medical Corporation | $196 | Travel and Lodging | Cash or cash equivalent | Navicross Device, Vascular Access | 2019 | |
| 2019-07-26 | Terumo Medical Corporation | $19 | Food and Beverage | Cash or cash equivalent | Navicross Device, Vascular Access | 2019 | |
| 2019-07-26 | Terumo Medical Corporation | $14 | Food and Beverage | Cash or cash equivalent | Glidesheath Device, Lesion Access | 2019 | |
| 2019-07-25 | Terumo Medical Corporation | $129 | Food and Beverage | Cash or cash equivalent | Navicross Device, Vascular Access | 2019 | |
| 2019-07-25 | Terumo Medical Corporation | $79 | Travel and Lodging | Cash or cash equivalent | Navicross Device, Vascular Access | 2019 | |
| 2019-07-16 | Merit Medical Systems Inc | $6,550 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-06-07 | Terumo Medical Corporation | $346 | Travel and Lodging | Cash or cash equivalent | Navicross Device, Vascular Access | 2019 | |
| 2019-05-25 | Merit Medical Systems Inc | $7,800 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-05-25 | Merit Medical Systems Inc | $7,300 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-04-18 | Chiesi USA, Inc. | $14 | Food and Beverage | Cash or cash equivalent | KENGREAL Drug, CARDIOVASCULAR | 2019 | |
| 2019-03-30 | Merit Medical Systems Inc | $2,500 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-03-09 | Merit Medical Systems Inc | $4,800 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-03-03 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2023-05-10 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $28,287 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2022-12-31 | Merck Sharp & Dohme LLC | GEORGIA HEART SPECIALISTS, LLC COVINGTON | $450 | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $32 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $32 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $1,204 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $32 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $389 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $389 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $32 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-16 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $389 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $663 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-25 | Esperion Therapeutics, Inc. | GEORGIA HEART SPECIALISTS LLC | $244 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Covington, GA, county Newton County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Covington, GA | County Newton County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 14,584 | 118,152 | 10,940,407 |
| Population, 2020 census P1 | 14,192 | 112,483 | 10,711,908 |
| Median age B01002 | 37.8 | 36.8 | 37.6 |
| Under 18 B01001 | 25.1% | 25.3% | 23.2% |
| 65 and over B01001 | 16.8% | 13.4% | 15.0% |
| Households B11001 | 5,662 | 41,203 | 4,074,366 |
| Foreign born B05002 | 6.2% | 7.0% | 11.2% |
| Median household income B19013 | $58,810 | $77,179 | $77,353 |
| Median family income B19113 | $72,262 | $88,631 | $93,754 |
| Per capita income B19301 | $32,109 | $33,172 | $40,924 |
| Poverty rate B17001 | 20.4% | 12.3% | 13.4% |
| Unemployment rate B23025 | 7.3% | 6.6% | 5.1% |
| Civilian labor force B23025 | 7,098 | 59,234 | 5,496,061 |
| Mean commute (minutes) B08013 | 36.5 | 35.9 | 28.3 |
| Bachelor's degree or higher B15003 | 27.2% | 25.0% | 34.9% |
| Housing units B25001 | 6,217 | 43,619 | 4,541,835 |
| Owner-occupied B25003 | 48.6% | 73.8% | 65.7% |
| Renters B25003 | 51.4% | 26.2% | 34.3% |
| Median home value B25077 | $301,900 | $265,000 | $303,300 |
| Median gross rent B25064 | $1,191 | $1,439 | $1,393 |
| White, not Hispanic B03002 | 39.3% | 38.8% | 49.1% |
| Black B03002 | 49.1% | 47.3% | 30.7% |
| Hispanic or Latino B03002 | 7.9% | 7.1% | 11.0% |
| Asian B03002 | 0.4% | 1.5% | 4.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Covington, GA.
Comments